TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05052996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Tablets administered orally without regard to food
Study: NCT05247905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05266495

Intervention type: OTHER
Intervention: Brolucizumab
Description: There is no treatment allocation. Patients administered brolucizumab by prescription will be enrolled.
Study: NCT06150261

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AvailOm
Description: 5 capsules taken once daily with main meal

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 capsules taken once daily with main meal
Study: NCT05621733

Intervention type: OTHER
Intervention: ruxolitinib
Description: Prospective observational study. There is no treatment allocation. Patients prescribed with ruxolitinib in the commercial setting are eligible to enroll into this study.
Study: NCT06492135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: survodutide
Description: survodutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: survodutide
Description: survodutide
Study: NCT04740567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: The cognitive training program regimen and its degree of difficulty will be tailored to the patient's current level of cognitive functioning and interests. Patients will be asked to work through progressively more challenging exercises pertaining to orientation, attention, problem-solving, and memory. These cognitive training exercises will be significantly difficult but when they can be completed easily (\>85% mastery), their difficulty will be increased, and this process will be repeated as appropriate. They will also perform puzzles, games, or cognitive tasks related to their hobbies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: Goal management training will (1) teach patients compensatory strategies such as stop techniques \[e.g., to stop and think about consequences of a decision before making it\]; (2) help them to take complex tasks and divide them into manageable subtasks to increase the likelihood of completing the task; and (3) enable them to learn to regain cognitive control when their behavior becomes incompatible with their intended goals. GMT is anchored in sustained and vigilant attention theory and it enables patients to actively attend to higher order goals critical to functioning. GMT is tailored to the individual needs of the patient. During the initial session, the Cognitive Intervention Specialist will meet with the subject and their family member or caregiver to identify these functional and cognitive deficiencies.
Study: NCT05029128

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Endurance exercise intervention
Description: All participants engage in treadmill walking 4 days/week, 60 minutes/day, at 70-80% of HRmax for 4 weeks.
Study: NCT06259006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: 4mg capsules taken orally in three divided doses to a total daily dose of 20mg/m2 (maximum dose 24mg/day) for three days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules taken orally three times daily for three days
Study: NCT05422066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
Study: NCT06061666

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tilia tomentosa Concentrated - Glycerine macerate (C-GM) vs Placebo (1 gtt/10 kg/day before bedtime for 15 days)
Description: Self-administration of the food supplement or placebo (1 gtt/10 kg/day before bedtime for 15 days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tilia tomentosa Concentrated - Glycerine macerate (C-GM) vs Placebo (1 gtt/10 kg/day before bedtime for 15 days)
Description: Self-administration of the food supplement or placebo (1 gtt/10 kg/day before bedtime for 15 days)
Study: NCT06266403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Communicative Interaction
Description: Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the ____ this time, and the listener will click on it. After the listener has made their selection, both participants will receive feedback on trial success.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clear Speech
Description: PALS and age-matched speakers will read critical words consisting of target segments (e.g., hid, ship, net) in random order four times. These words will be embedded in the carrier phrase Click on the ___ this time. Participations will be instructed to overenunciate the critical words.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unstructured communicative interaction
Description: Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. The pairs will be presented with two different versions of the same picture with eight differences chosen to elicit the same target segments (e.g., hid, ship, net). These pictures will be modified from the LUCID corpus. In total, pairs will complete four picture sets per session. Pairs will be given 5 minutes for each picture set.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clear Speech Structured Communicative Interaction
Description: Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the ____ this time, and the listener will click on it. The speaker will be instructed to overenunciate the critical words. After the listener has made their selection, both participants will receive feedback on trial success.
Study: NCT06496412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Description: Take fecal microbiota capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take placebo capsules.
Study: NCT05147480

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: internet-based mother-baby yoga
Description: Mother-baby yoga group classes given by physiotherapists via Zoom Video Communications
Study: NCT05112887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Therapy
Description: Osteopathic Manipulative Therapy is a type of hands-on manipulative medicine where the physician uses their hands and knowledge of anatomy to encourage the human body to reattain homeostasis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Osteopathic Manipulative Therapy
Description: Osteopathic Manipulative Therapy is a type of hands-on manipulative medicine where the physician uses their hands and knowledge of anatomy to encourage the human body to reattain homeostasis.
Study: NCT04428047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bintrafusp alfa
Description: bintrafusp alfa will be administered by intravenous infusion over 60 minutes at a dose of 1200 mg on Day1 and Day15
Study: NCT06173999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554/CHOP
Description: SHR2554 with CHOP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554/CHOEP
Description: SHR2554 with CHOEP
Study: NCT05845359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: One group will receive 10mg of methadone upon induction, while the other will receive a saline solution as placebo. We will see the effectiveness of methadone on postoperative pain management, while monitoring for opioid-related side effects.
Study: NCT05973136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation program based on cardiorespiratory principles
Description: The intervention consists of a hybrid program. The participant will receive rehabilitation sessions in presence (aerobic component of the intervention based on maximal oxygen uptake measured before intervention by means on a ergospirometric test) and at home via a telerehabilitation platform. The length of the intervention is 12 weeks. For the in-presence sessions, they are going to be 75 minutes, 2x/week. For the at-distance sessions, they are going to be 45 minutes, 1x/week in groups of 3 to 4 participants. The intervention will consist of a warm-up, endurance, postural, and strengthening exercises, cool down and respiratory exercises. An exercise book with final recommendations is provided to the participants at the end of the intervention.
Study: NCT06064344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intralesional Rituximab Injection

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Involved Site Radiation Therapy
Description: Involved Site Radiation Therapy
Study: NCT05033392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: A domestic PD-1 antibody
Study: NCT06547476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib
Description: Tucidinostat (chidamide)，30mg, po., biw PD-1 inhibitor (tislelizumab), 200mg, ivgtt. d1, q3w anlotinib, 12mg, po., d1-14, q3w
Study: NCT05971966

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality technique
Description: They would be receiving treatment as follow:~Specific exercises by using virtual reality with conventional treatment. The VR game included holopoint,hot squat and portal stories that will target the hamstring, quadriceps and gluteas muscles.Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: virtual reality gaming exercises Conventional PT including patellar mobilization+ ultrasound on anterior knee in supine lying + stretching of ITB . Frequency: 10 reps with 5 sec hold for 3 times/week for 4 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy technique
Description: They would be receiving treatment as follow:~Muscle energy technique of quadriceps and hamstring muscles. Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Muscle energy technique to improve range of motion.~Conventional PT including patellar mobilization + ultrasound on anterior knee in supine lying + stretching of ITB. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins
Study: NCT06303661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-ablative Radiofrequency
Description: There are two electrodes: one active, which will be used on the penis, using a non-lubricated condom from the Blowtex brand, using pharmaceutical glycerin to emit radiofrequency inside and outside the condom, and another electrode, dispersive, wrapped in PVC-type plastic film, coupled to the region of the patient's penis where there is no fibrotic plaque, which will act as earth and the temperature to be used in the treatment will be 38°C. When the desired heating is reached, the device maintains the temperature and thus the radiofrequency application will be maintained for 2 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity Shock Wave Therapy
Description: The equipment's applicator is covered with transparent PVC film and non-alcoholic gel is used as a coupling medium between the applicator and the penis. The following parameters are used: frequency of 10Hz, energy of 120mJ and 2,000 shots in the fibrotic plaque.
Study: NCT03868943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soliramfetol
Description: Solriamfetol will be dosed by flexible dose titration starting at 75 mg daily in all patients and escalating after 7 days (1 week) to 150 mg daily and then after 7 days to 300 mg daily for a total duration of 3 weeks (flexible dose titration period).
Study: NCT04770480

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (SC)
Description: No attempt will be made to change usual care practice after surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Pain Management Pathway (EPM)
Description: Enriched Pain Management Pathway will be delivered by physical therapists trained to integrate physical therapy and mindfulness techniques grounded in a biopsychosocial context. The intervention will be delivered within the context of the post-operative physical therapy routine (the mindfulness approach will be integrated into the post-operative physical therapy care).
Study: NCT04951622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered as an IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as an IV infusion.
Study: NCT04955275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy Program (BrainHQ)
Description: Brain HQ games involving training cognitive abilities like memory and attention, made up of adapting tasks or creating our own.
Study: NCT05107167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic stimulation
Description: Electromagnetic stimulation of the phrenic nerve
Study: NCT04678648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSC-1255 Dose Escalation
Description: Phase 1a will enroll 30-40 participants to identify the dose limiting toxicity (DLT), recommended Phase 1b dose, and the safety and tolerability of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSC-1255 Dose Expansion
Description: Phase 1b will enroll 48-104 participants to further characterize the safety, pharmacology, and clinical efficacy of RSC-1255. RSC-1255 is administered orally twice daily, without food. Each cycle is 21 days.
Study: NCT05313867

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutri VX 1
Description: 1 sequence of 10 tablets (one intake)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sequence of 10 tablets (one intake)
Study: NCT05772845

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acute (24-hour) abstinence
Description: Participants will be asked to abstain from all tobacco/nicotine for 24 hours prior to the visit
Study: NCT05187273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elastance Group
Description: Fluids are given based on dynamic elastane value
Study: NCT06299488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sip2Sleep: Montmorency Cherry and Apocynum Venetum
Description: See arm description
Study: NCT05277337

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alluzience
Description: Botulinum Toxin Type A (BoNT-A) for treatment of glabellar lines; Mode of administration: intramuscular injection
Study: NCT05772845

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acute (24-hour) abstinence
Description: Participants will be asked to abstain from all tobacco/nicotine for 24 hours prior to the visit

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acute (24-hour) abstinence
Description: Participants will be asked to abstain from all tobacco/nicotine for 24 hours prior to the visit

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ad libitum smoking/vaping
Description: Participants will be asked to smoke/vape as usual during the 24 hours prior to the visit

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ad libitum smoking/vaping
Description: Participants will be asked to smoke/vape as usual during the 24 hours prior to the visit

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ad libitum smoking/vaping
Description: Participants will be asked to smoke/vape as usual during the 24 hours prior to the visit
Study: NCT06097520

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR Intervention
Description: For the VR Intervention a VR head-mounted display, the Pico G2 4K, will be used. This intervention involves wearing VR glasses and experiencing non-interactive videos with sound through a headset. The footage consists of different immersive 360-degree scenarios from natural environments (e.g., forest), while corresponding sounds, meditation or classical music harmoniously tuned to these scenarios and are played through noise-cancelling headphones.
Study: NCT06186687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofunctional therapy exercise
Description: Myofunctional therapy involves various exercises to train muscles in the soft palate, tongue, face, and pharynx. Vocal letters are used to train the palatopharyngeus, palatoglossus, uvula, tensor veli palatine, and levator veli palatine muscles. Tongue exercises involve sliding the tongue to the upper and side surfaces of the teeth, placing the tip in front of the palate, and pressing and sucking the tongue up to the palate. Face exercises involve inflating the cheeks, gargling, and sucking the cheeks to exercise the orbicularis oris muscle and the buccinator muscle. Icing stimulates the mouth, producing a cold, chilling, and numbing effect, causing reflexive contraction of the palate, tongue, and pharyngeal muscles.
Study: NCT04982640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar yoga
Description: 60 minute group-classes of Iyengar yoga delivered twice weekly for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exercise
Description: 60 minutes, twice weekly for 12 weeks, group-based walking program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Counseling
Description: One, 30-minute session with registered dietitian

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: One, 30-minute session with registered dietitian
Study: NCT05590598

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Azelastine + Mometazone, nasal spray
Description: 140 mcg + 50 mcg/dose (Sandoz d.d., Slovenia), one actuation in each nostril twice daily, morning and evening (recommended interval between administrations is approximately 12 hours), for 14 consecutive days.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Momat Rhino Advance
Description: 140 µg + 50 µg/dose - one actuation into each nostril twice daily - morning and evening (interval between administrations is 12 hrs), corresponding to 560 µg/day of azelastine and 200 µg/day of mometasone for 14 consecutive days
Study: NCT05340205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Patients will receive 1 gm tranexamic acid diluted in 20 ml of Glucose 5% 15 minutes prior to skin incision and a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following delivery of the baby.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Patients will receive 400 microgram misoprostol which will be inserted inside the uterus near the cornu after delivery of the placenta and a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h).~.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patients will receive an IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby.
Study: NCT05753826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: 20mg/kg，D1，q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzuloparib
Description: 100 mg bid
Study: NCT05674474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib
Description: Administered orally as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib
Description: Administered orally as tablets.
Study: NCT02120755

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AmnioClear™ Human Allograft Amniotic Membrane